180 related articles for article (PubMed ID: 37518874)
1. In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology.
Opriţa A; Dobrescu MA; Manea EV; Popescu ŞO; Sevastre AS; Pîrvu AS; Buzatu IM; Tache DE
Rom J Morphol Embryol; 2023; 64(2):173-180. PubMed ID: 37518874
[TBL] [Abstract][Full Text] [Related]
2. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
4. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
[TBL] [Abstract][Full Text] [Related]
5. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
Dranitsaris G; Schmitz S; Broom RJ
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
[TBL] [Abstract][Full Text] [Related]
6. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830
[TBL] [Abstract][Full Text] [Related]
7. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
8. Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Takada M; Yasui T; Oka T; Shioyama W; Kuroda T; Nakai Y; Nishimura K; Mukai M; Fujita M
Int Heart J; 2018 Sep; 59(5):1174-1179. PubMed ID: 30158382
[TBL] [Abstract][Full Text] [Related]
9. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
10. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
O'Sullivan C; Edgerly M; Velarde M; Wilkerson J; Venkatesan AM; Pittaluga S; Yang SX; Nguyen D; Balasubramaniam S; Fojo T
J Clin Endocrinol Metab; 2014 Apr; 99(4):1291-7. PubMed ID: 24423320
[TBL] [Abstract][Full Text] [Related]
11. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
[TBL] [Abstract][Full Text] [Related]
12. Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events.
Imano H; Kato R; Ijiri Y; Hayashi T
Toxicol In Vitro; 2021 Mar; 71():105063. PubMed ID: 33271325
[TBL] [Abstract][Full Text] [Related]
13.
Lee HG; Lim GH; An JH; Park SM; Seo KW; Youn HY
J Vet Sci; 2024 Jan; 25(1):e1. PubMed ID: 38311316
[TBL] [Abstract][Full Text] [Related]
14. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
15. The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
Ehrhardt M; Craveiro RB; Velz J; Olschewski M; Casati A; Schönberger S; Pietsch T; Dilloo D
J Cell Mol Med; 2018 Apr; 22(4):2153-2161. PubMed ID: 29377550
[TBL] [Abstract][Full Text] [Related]
16. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
Heine A; Held SA; Daecke SN; Riethausen K; Kotthoff P; Flores C; Kurts C; Brossart P
PLoS One; 2015; 10(6):e0128897. PubMed ID: 26042424
[TBL] [Abstract][Full Text] [Related]
17. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.
Bellesoeur A; Carton E; Alexandre J; Goldwasser F; Huillard O
Drug Des Devel Ther; 2017; 11():2801-2811. PubMed ID: 29033542
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
19. Axitinib for renal cell carcinoma.
Sonpavde G; Hutson TE; Rini BI
Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
Cella D; Escudier B; Rini B; Chen C; Bhattacharyya H; Tarazi J; Rosbrook B; Kim S; Motzer R
Br J Cancer; 2013 Apr; 108(8):1571-8. PubMed ID: 23579211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]